Eli Lilly & Co.'s antidepressant Cymbalta has come under scanner as the Food and Drug Administration has canceled a meeting to review it for a new use against chronic pain.

Reports on Tuesday said is a statement that the meeting scheduled for January 28 was canceled. It was done to give FDA time for reviewing new information of Cymbalta for chronic pain caused by osteoarthritis. Last summer the company had put forward a new application that included a study of Cymbalta and a new data from a study of lower back pain was also there.

The application was later withdrawn by Lilly in November 2008 after the methodology was questioned by the FDA reviewers. Some of the company's trials were dosed.

The Indianapolis-based company did not return calls placed on Tuesday immediately.

Cymbalta is Lilly's second-best selling product, behind the anti-psychotic Zyprexa. A sale of $2.24 billion was generated by the drug through the first three quarters of 2009.

The company said, "We also continue to respond to questions from FDA staffers ... as well as continue our routine safety monitoring that isn't specific to the chronic pain application."

On the New York Stock Exchange Lilly shares fell 1.8 percent to $35.19.